The estimated Net Worth of Chad Gassert is at least 22.6 百万$ dollars as of 1 July 2024. Mr Gassert owns over 20,000 units of ANI Pharmaceuticals Inc stock worth over 10,496,036$ and over the last 3 years he sold ANIP stock worth over 12,090,400$.
Mr has made over 11 trades of the ANI Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of ANIP stock worth 1,268,800$ on 1 July 2024.
The largest trade he's ever made was selling 20,000 units of ANI Pharmaceuticals Inc stock on 1 July 2024 worth over 1,268,800$. On average, Mr trades about 14,000 units every 56 days since 2021. As of 1 July 2024 he still owns at least 193,226 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Mr Gassert stock trades at the bottom of the page.
Chad Gassert is the Sr. VP of Corp. Devel. & Strategy at ANI Pharmaceuticals Inc.
Chad's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over 183,421,501$ worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth 2,783,357$ . The most active insiders traders include Arthur Przybyl、Venture Partners Ii Lp Meri...、Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of 1,378,805$. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth 14,905$.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: